Collaboration with Janssen and Eli Lilly to address lack of paediatric medications
Pharmaceutical Technology
JANUARY 23, 2023
In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).
Let's personalize your content